Ligand Targretin
Executive Summary
Bexarotene 75 mg capsules approved Dec. 29 for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. The drug received a "1P" classification from FDA denoting a new molecular entity undergoing a priority review. FDA's Oncologic Drugs Advisory Committee recommended at its Dec. 13 meeting that Targretin be used in advanced CTCL patients, not in early disease ("The Pink Sheet" Dec. 20, 1999, p. 10)